21:50 , Dec 1, 2017 |  BC Week In Review  |  Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open, free access to select molecules in the preclinical stage. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable...
22:03 , Nov 20, 2017 |  BC Extra  |  Company News

Boehringer launches open-access preclinical platform

Boehringer Ingelheim GmbH (Ingelheim, Germany) launched a platform to provide researchers worldwide with open and free access to select preclinical-stage molecules. The platform, opn.ME , comprises 19 compounds that Boehringer has deemed suitable for preclinical...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
21:01 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia Mouse studies suggest inhibiting signaling between CCL3 and its receptors, CCR1 and CCR5 , could help treat juvenile myelomonocytic leukemia (JMML) in Noonan syndrome patients harboring activating SHP-2 mutations. In a mouse model...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Chemical reaction for adding nitriles to benzylic carbons to enable efficient synthesis of drug precursors and drug-like molecules

Chemistry TECHNOLOGY: Synthetic chemistry A method for adding nitrile functional groups to benzylic carbons could enable efficient chemical synthesis of drug precursors and drug-like molecules. The room-temperature reaction utilized trimethylsilyl cyanide and a copper-based catalyst...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned rights to CCX354 , a CC chemokine receptor 1 (CCR1) antagonist that has completed Phase II testing for rheumatoid arthritis (RA). Last year, GSK exercised an option under a 2006 deal...
01:17 , Dec 4, 2013 |  BC Extra  |  Company News

GSK returns remaining ChemoCentryx programs

ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to exercise its option for CCX168 , a small molecule complement receptor 5a (C5aR; CD88 ) inhibitor in the Phase II CLEAR trial for antineutrophil cytoplasmic...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Amphiregulin (AREG); monocyte chemoattractant protein-1 (MCP-1; CCL2); chemokine CC motif ligand 7 (CCL7; MCP3; SCYA6); CC chemokine receptor 1...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned all rights to vercirnon. In August, the pharma suspended the Phase III program for the CC chemokine receptor 9 ( CCR9 ) antagonist after the product missed the primary and secondary...
01:29 , Sep 19, 2013 |  BC Extra  |  Company News

ChemoCentryx regains vercirnon rights from GSK

ChemoCentryx Inc. (NASDAQ:CCXI) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) returned all rights to vercirnon. In August, the pharma suspended the Phase III program for the CC chemokine receptor 9 ( CCR9 ) antagonist after the product...